Next 10 |
home / stock / optn / optn articles
YARDLEY, Pa., May 17, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and thr...
Shares of Doximity, Inc. (NYSE:DOCS) rose sharply in today's pre-market trading reported stronger-than-expected financial results for the four...
YARDLEY, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and thr...
YARDLEY, Pa., April 25, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and t...
YARDLEY, Pa., April 04, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and t...
U.S. stocks traded mixed toward the end of trading on Wednesday. The Dow traded up 0.05% to 36,143.40 while the NASDAQ fell 0.06% to 14,221.51...
Shares of AeroVironment, Inc. (NASDAQ: AVAV) moved lower during Wednesday’s session following second-quarter results. AeroVironment posted ad...
U.S. stocks traded mostly flat midway through trading, with the S&P 500 turning lower on Wednesday. The Dow traded up 0.01% to 36,126.75 w...
U.S. stocks traded higher this morning, following the release of economic reports on Wednesday. Following the market opening Wednesday, the Dow tra...
News, Short Squeeze, Breakout and More Instantly...
YARDLEY, Pa., June 27, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that XHANCE ® (fluticasone propionate) has been added to Express Scripts’ nationa...
YARDLEY, Pa., May 17, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the H.C...
2024-05-15 10:30:03 ET Lake Street analyst issues BUY recommendation for OPTN on May 15, 2024 08:43AM ET. The previous analyst recommendation was Buy. OPTN was trading at $1.13 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analy...